Registration Dossier

Diss Factsheets

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
From October 16, 2017 to January 2, 2018
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2018
Report date:
2018

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
GLP compliance:
yes
Test type:
acute toxic class method
Limit test:
yes

Test material

Constituent 1
Chemical structure
Reference substance name:
2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[2-[3-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]diazenyl]-6-[2-[2-sulfo-4-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]diazenyl]-, sodium salt (1:5)
EC Number:
815-135-8
Cas Number:
1386899-40-6
Molecular formula:
C26H25N5O22S7.5Na
IUPAC Name:
2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[2-[3-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]diazenyl]-6-[2-[2-sulfo-4-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]diazenyl]-, sodium salt (1:5)
Test material form:
solid: particulate/powder

Test animals

Species:
rat
Strain:
Sprague-Dawley
Sex:
female
Details on test animals or test system and environmental conditions:
- Source: BioLASCO Taiwan Co., Ltd (Taipei, Taiwan)
- Age at study initiation: about 8 week old
- Housing: two animals per cage
- Water: ad libitum
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 55 ± 15%
- Photoperiod (hrs dark / hrs light): 12-hrs dark / 12-hrs light cycle

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
water
Doses:
For Group 1: 2,000 mg/kg B.W.
For Group 2: 2,000 mg/kg B.W.
No. of animals per sex per dose:
For Group 1: Three
For Group 2: Three

Results and discussion

Effect levels
Sex:
female
Dose descriptor:
LD50
Effect level:
> 2 000 mg/kg bw
Based on:
test mat.

Any other information on results incl. tables

Table 1. Body weight of the rats during the study period

Animal I.D.

Dosing volume

(mL)

Body weight (g)

Weight changes

(g)

Day 1

Day 14

Group 1

01F

2.2

210.7

243.2

+32.5

02F

2.1

201.9

236.9

+35.0

03F

2.3

222.0

254.3

+32.3

Group 2

04F

2.2

210.6

241.1

+30.5

05F

2.2

218.5

247.5

+29.0

06F

2.1

205.5

219.3

+13.8

Table 2. Clinical observation of the rats

Animal I.D.

Clinical sign observation

30 mins

4 hrs

D2

D3

D4

D5

D6

D7

D8

D9

D10

D11

D12

D13

D14

Group 1

01F

N

N

N

N

N

N

N

N

N

N

N

N

N

N

N

02F

N

N

N

N

N

N

N

N

N

N

N

N

N

N

N

03F

N

N

N

N

N

N

N

N

N

N

N

N

N

N

N

Group2

04F

N

N

N

N

N

N

N

N

N

N

N

N

N

N

N

05F

N

N

N

N

N

N

N

N

N

N

N

N

N

N

N

06F

N

N

N

N

N

N

N

N

N

N

N

N

N

N

N

N: Normal.

D2-D14: Day 2-Day 14.

 

Table 3. Results of gross necropsy examination

Animal I.D.

Dose

Gross lesion

Group 1

01F

2,000 mg/kg B.W.

No significant lesion founded

02F

No significant lesion founded

03F

No significant lesion founded

Group 2

04F

2,000 mg/kg B.W.

No significant lesion founded

05F

No significant lesion founded

06F

No significant lesion founded

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Conclusions:
According to OECD 423 test method, the LD50 of CR SB37 was greater than 2000 mg/kg B.W.. Therefore, CR SB37 was Unclassified based on GHS criteria.
Executive summary:

This test using the procedures outlined in the SuperLab for M62-170900014001EN which is based on the SOP (SOPP-341) for the OECD 423 and OECD 423 (OECD, 2001). A total of 6 female Sprague-Dawley rats were orally dosed with CR SB37 in three animals each group, at 2000 mg/kg b.w. for both Group 1 and Group 2 in limit test. All animals tolerated the test article well with increasing body weights and no mortality or gross lesions findings reported. In absence of mortality or other significant clinical signs of toxicity, LD50 of CR SB37 was greater than 2,000 mg/kg.

Categories Display